XR Securities’s Crescent Biopharma CBIO Stock Holding History

XR Securities’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-104	Closed	-$15K	–	410
2021 Q4	$15K	Buy	+104	New	+$18.9K	﹤0.01%	388

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

XR Securities's CBIO Position: Q1 2022 in Review

XR Securities sold out of Crescent Biopharma (CBIO) in Q1 2022, closing a stake of 104 shares — an estimated $15K sold.

XR Securities first reported a position in CBIO in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 43 funds tracked by Wall St. Rank hold CBIO as of Q1 2022.

XR Securities reported no remaining Crescent Biopharma position as of Q1 2022 after selling out during the quarter.
XR Securities sold 104 Crescent Biopharma shares in Q1 2022, an estimated $15K.
XR Securities first reported a position in Crescent Biopharma in Q4 2021 and held it in 1 quarter.
XR Securities's Crescent Biopharma position peaked at $15K in Q4 2021.
43 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2022.

Based on XR Securities's 13F filing for Q1 2022, filed 14 Apr 2022.